Phase 3 Clinical Trials With Primary Completion Dates in June 2022
This is a list of Phase 3 trials with primary completion dates in June 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | 2022-06-01 | Phase 3 | NCT04707768 | Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects |
| AORT | Artivion, Inc. | 2022-06-01 | Phase 3 | NCT04142658 | PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban |
| ATNM | Actinium Pharmaceuticals, Inc. | 2022-06-01 | Phase 3 | NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia |
| ATRA | Atara Biotherapeutics, Inc. | 2022-06-01 | Phase 3 | NCT03394365 | Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy |
| CLVS | Clovis Oncology, Inc. | 2022-06-01 | Phase 3 | NCT02975934 | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency |
| CNCE | Concert Pharmaceuticals, Inc. | 2022-06-01 | Phase 3 | NCT04797650 | A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA2) |
| EBS | Emergent BioSolutions Inc. | 2022-06-01 | Phase 3 | NCT05072080 | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 |
| EPZM | Epizyme, Inc. | 2022-06-01 | Phase 3 | NCT04224493 | Study in Subjects With Relapsed/Refractory Follicular Lymphoma |
| EXEL | Exelixis, Inc. | 2022-06-01 | Phase 3 | NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma |
| FAMDF | Futura Medical plc | 2022-06-01 | Phase 3 | NCT04984993 | Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction |
| FOLD | Amicus Therapeutics, Inc. | 2022-06-01 | Phase 3 | NCT04049760 | Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease |
| NEPH | Nephros, Inc. | 2022-06-01 | Phase 3 | NCT04591015 | Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19 |
| NKTR | Nektar Therapeutics | 2022-06-01 | Phase 3 | NCT03729245 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) |
| NVAX | Novavax, Inc. | 2022-06-01 | Phase 3 | NCT05372588 | Phase 3 Booster Study for the SARS-CoV-2 rS Vaccines |
| RLMD | Relmada Therapeutics, Inc. | 2022-06-01 | Phase 3 | NCT05081167 | A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) |
| TVTX | Travere Therapeutics, Inc. | 2022-06-01 | Phase 3 | NCT03493685 | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) |
| URGN | UroGen Pharma Ltd. | 2022-06-01 | Phase 3 | NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) |